Cellular LDL Uptake Assessment for Lipid Lowering Therapy Response

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for determining the likelihood of a subject's response to lipid-lowering therapy and assessing the risk of atherosclerosis and cardiovascular disease are inadequate, as they do not effectively quantify cellular mechanisms, leading to delayed cholesterol level regulation and increased cardiovascular risk.

Innovation Solution

A method that determines the quantitative values of low-density lipoprotein (LDL) uptake, LDL receptor expression, lipid storage capability, and lipid mobilization capability in cells from a biological sample, which are indicative of the subject's response to lipid-lowering therapy and cardiovascular disease risk.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If statin therapy is administered to subjects with hypercholesterolemia, then cholesterol levels may be reduced over time, but the response time is prolonged and many subjects do not achieve target cholesterol levels

Engineering Contradiction:

Improvecholesterol level reduction effectivenessVSAvoidtime to achieve target cholesterol level

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent performs preliminary assessment of cellular LDL uptake capability, LDLR expression, lipid storage capability, and lipid mobilization capability before initiating statin therapy. This preliminary action identifies subjects who are likely to respond to therapy, enabling early intervention and timely adjustment of treatment strategies to achieve target cholesterol levels more quickly.

Inventive Principle:

Principle #10Preliminary action

2Measurement precision

If conventional cholesterol monitoring methods are used, then treatment response can be assessed, but cellular mechanisms cannot be quantified leading to delayed intervention

Engineering Contradiction:

Improvetreatment response assessmentVSAvoidcellular mechanism data

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent replaces conventional mechanical/chemical cholesterol monitoring methods with a cellular-based assessment system. By measuring cellular LDL uptake, LDLR expression, lipid storage, and lipid mobilization capabilities, the patent provides direct quantification of the cellular mechanisms underlying cholesterol metabolism, enabling precise treatment response assessment and early identification of non-responders.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS20240044924A1Method for determining a likelihood of a subject to respond to lipid lowering therapy

Publication Date: 2024.02.08 MONCYTE HEALTH OY

AI summary

A method for determining a likelihood of a subject to respond to lipid lowering therapy is disclosed. The method may comprise determining a quantitative value of the ability of cells obtained from a biological sample of the subject to take up low-density lipoprotein (LDL), a quantitative value of the expression of LDL receptor (LDLR) in the cells, a quantitative value of the lipid storage capability of the cells, and/or a quantitative value of the lipid mobilization capability of the cells; wherein the quantitative value of the ability of the cells to take up LDL, the quantitative value of the expression of LDLR in the cells, the quantitative value of the lipid storage capability of the cells, and/or the quantitative value of the lipid mobilization capability of the cells is/are indicative of the likelihood of the subject to respond to lipid lowering therapy.